Retatrutide: What It Is and Why All the Hype

Semaglutide (Ozempic) showed just how strongly a single hormonal signal can affect hunger and body weight. Tirzepatide (Mounjaro) added a second. Retatrutide goes one step further: it combines activity at three different receptors in a single molecule.

That combination has made it one of the most closely watched drugs in development. And it is not merely an interesting mechanism on paper. In clinical trials, retatrutide produced average weight reductions that would have seemed almost unthinkable for an injectable treatment just a few years ago.^1,2 At the same time, it remains an investigational drug without approval for routine use in either the EU or the US.^3,4

This article therefore covers the essentials: what retatrutide is, how it differs from the better-known GLP-1 receptor agonists, what studies have shown so far, and why it has generated so much hype.

Looking for something more practical? Go straight to Retatrutide in a Diet: Split Dosing, Lower Doses, and Why Not to Copy Clinical Trials or Retatrutide: My Personal Experience and Side Effects.

What is retatrutide?

Retatrutide, also known during development as LY3437943, is a synthetic peptide being developed by Eli Lilly. It is a triple receptor agonist—a single molecule that activates the GLP-1, GIP, and glucagon receptors.⁵

An agonist is a substance that binds to a receptor and activates its signaling. Retatrutide is therefore not a mixture of three drugs or a combination of three injections. It is designed so that one molecule mimics part of the activity of three natural hormones involved in regulating food intake, blood glucose, and energy metabolism.

In clinical trials, it is administered once weekly. Its prolonged action results from modifications that slow its breakdown in the body. This makes it a candidate treatment for obesity, type 2 diabetes, and some complications associated with excess weight. For now, however, it is more accurate to call it a drug in development than an available treatment.

The name “GLP-3” sometimes appears online. It is not a scientific term or a third version of GLP-1. It is simply an informal shorthand referring to the three receptors that retatrutide activates.

One, two, and three receptors

The simplest way to place retatrutide in context is to look at how the better-known molecules have evolved:

The number of receptors alone does not mean that one molecule is automatically “stronger” or better. What matters is how strongly it activates each receptor, in what balance, and how the human body responds to their combined signaling. The table does, however, show why retatrutide is described as the next step in the development of these drugs.

GLP-1 is the best-known component. Its signaling supports satiety, affects insulin and glucagon after meals, and may slow gastric emptying. We explain this mechanism in more detail in our separate article What Is GLP-1 and How Do GLP-1 Receptor Agonists Work?.

GIP is another hormone released after a meal. It is particularly involved in the insulin response and, together with GLP-1, may alter food intake and the metabolic response to nutrients. Tirzepatide (Mounjaro) already combines activity at the GLP-1 and GIP receptors.

The glucagon receptor is the most interesting and least intuitive component. Among other functions, glucagon helps maintain blood glucose by signaling the liver to release glucose. Activating its receptor may also affect the use of energy stores and energy expenditure. In retatrutide, this third pathway is thought to contribute to the resulting weight loss, but the studies conducted in humans so far do not allow its precise contribution to be separated easily from the effects of GLP-1 and GIP.^5,1

Retatrutide therefore does not work like three independent switches. Its overall effect arises from their combined influence on hunger, satiety, glucose processing, and energy balance.

Why has retatrutide generated so much hype?

The first major wave of interest followed a published phase 2 trial in 2023. It included 338 adults with obesity, or with overweight and at least one weight-related complication. After 48 weeks, the highest-dose group had lost an average of 24.2% of their body weight, compared with 2.1% in the placebo group.¹

That was an exceptionally large effect. It does not mean that everyone will lose a quarter of their body weight, nor can the figure be compared directly with results for a different molecule in a different trial. It did show, however, that triple agonism was more than an interesting theoretical concept.

Phase 3 results have since followed. In TRIUMPH-1, people with obesity or overweight but without diabetes lost an average of 28.3% of their body weight over 80 weeks at the highest dose studied. In the subgroup with a higher starting BMI that continued through week 104, the average reduction reached 30.3%.²

TRIUMPH-4 reported a similarly pronounced result in people with obesity and knee osteoarthritis: an average weight reduction of 28.7% over 68 weeks at the highest dose.⁶ Other phase 3 trials have also reported positive results in people with type 2 diabetes, severe obesity, and cardiovascular disease.⁷

It is important to distinguish the quality of this evidence. The phase 2 trial was published in a peer-reviewed scientific journal. For some of the more recent phase 3 results, we currently have detailed but still summary-level data announced by the manufacturer; full publications and independent evaluation of all the results may follow later.

The hype is therefore not based only on retatrutide targeting three receptors. It mainly reflects the fact that the substantial weight reduction seen in the smaller trial was later also observed in larger phase 3 trials. At the same time, there is still no completed direct head-to-head evidence showing that retatrutide is better for a particular person than tirzepatide (Mounjaro) or another treatment.

What do we know about adverse effects so far?

The most common adverse effects are consistent with those seen with other drugs acting through GLP-1: nausea, diarrhea, vomiting, and constipation. In the phase 2 trial, gastrointestinal adverse effects were dose-related and mostly mild to moderate. Slower dose escalation improved tolerability.¹

The same trial also found a dose-dependent increase in heart rate. It peaked at around week 24 and then declined. Newer trials continue to monitor not only common adverse effects, but also long-term effects on the heart, blood vessels, kidneys, and other organs.

We also now have some initial data on body composition. In a study of people with type 2 diabetes, most of the weight lost came from fat mass; the ratio of fat mass to lean mass lost was similar to that seen with other methods of weight loss.⁸ This does not mean that muscle is automatically protected, nor that the finding can be extrapolated to athletes or very lean people. It does show, however, that the question of “fat or muscle?” is no longer entirely without data.

What do we still not know about retatrutide?

Retatrutide now has far more data behind it than it did when the first phase 2 results appeared. However, we still lack experience with long-term use in routine clinical practice. We do not know exactly what outcomes will look like after several years, what will happen after treatment is stopped, or how the balance of benefits and risks will differ across groups of people.

It is also unclear how much the glucagon receptor actually contributes to the overall result. Clinical trials test the complete molecule, not each of its receptor pathways separately. The simple explanation that “GLP-1 switches off hunger and glucagon burns fat” is therefore appealing, but it oversimplifies the biology.

As of August 3, 2026, retatrutide is not approved for routine use in either the EU or the US. Eli Lilly has stated that it plans to submit an application for US approval in the first quarter of 2027.^7,3,4 Until then, it remains a drug in development, even though several phase 3 trials have already produced successful results.

Where to go next

This overview deliberately does not cover dosing, half-life, or the difference between a clinical-trial protocol and use during a diet. Those questions are addressed in our separate article Retatrutide in a Diet: Split Dosing, Lower Doses, and Why Not to Copy Clinical Trials.

If you are interested in how retatrutide affected hunger, portion sizes, and training in one specific case, you can also continue with Retatrutide: My Personal Experience and Side Effects. A personal experience is not clinical evidence, however, and cannot be generalized to other people.

The basic conclusion is simple: retatrutide is an investigational triple agonist of the GLP-1, GIP, and glucagon receptors. The hype around it has a real basis in trial results, but its definitive place in obesity treatment will only become clear after regulatory review, full publication of the data, and longer-term experience with its use.